Evidence Table E44. Binge eating disorder behavioral and drug treatment – part 8

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Agras, 199449 | Weight, kg | Weight, mean (SD)  Pretreatment  G1: 111.9 (17.4)  G2: 102.1 (15.7)  G3: 102.9 (15.8)  p=NS | Weight, mean (SD)  12 wks  G1: 112.7 (18.5)  G2: 102.7 (16.5)  G3: 100.9 (16.8)  G1 and G2 < G3, p<0.05  24 wks  G1: 107.0 (20.1)  G2: 100.7 (16.7)  G3: 100.4 (17.3)  p=NS  36 wks  G1: 105.9 (20.5)  G2: 100.5 (17.6)  G3: 99.2 (16.9)  p=NS  % Weight change, group X time, p<0.001  3 month f/u  G1: Lost 4.8 kg from baseline  G2: No change in weight from baseline  G3: Lost 4.15kg from baseline  p=NS | NR | NR | NR |

Evidence Table E44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brambilla, 200950 | NA | BMI, mean (SD)  G1: 39 (6)  G2: 34 (6)  G3: 34 (5)  Weight (kg), mean (SD)  G1: 105 (13)  G2: 86 (14)  G3: 88 (13) | BMI, mean (SD)  G1: 35 (6)  G2: 32 (8)  G3: 34 (8)  Group X time, p=0.01  Weight (kg), mean (SD)  G1: 93 (12)  G2: 84 (16)  G3: 87 (13)  Group X time, p=0.00 | 6m BMI  G1: 35 (SD 6), r=0.91 (table 2 reports significance as r)  G2: 32 (SD 8), r=NS (table 2 reports significance as r)  G3: 34 (SD 8), r=NS  One-way ANOVA showed significant decrease in BMI (p=0.00001) in G1 only  Two-way ANOVA for repeated measures showed significant effect of group (p=0.03, F=3.2), time (p=0.01, F=2.26) and group per time (p=0.01, F=2.26) on changes in BMI in the 3 groups  6m Weight (kg)  G1: 93 (SD 12), r=0.91 (table 2 reports significance as r)  G2: 84 (SD 16), r=NS (table 2 reports significance as r) | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brambilla, 200950  (continued) |  |  |  | G3: 87 (SD 13), r=NS (table 2 reports significance as r)  One-way ANOVA showed significant decrease in weight (p=0.00001) in G1 only  Two-way ANOVA for repeated measures showed significant effect of group (p=0.05, F=2.99), time (p=0.00003, F=5.45) and group per time (p=0.0017, F=3.42) on changes in weight in the 3 groups  Correlation analysis (Spearman's test):  G1: reduction in weight correlated negatively with change in EDI-2 perfectionism (p=0.04, T=-2.4), social insecurity (p=0.01, T=-3.0), and PDQ-4-R negativism (p=0.05, T=-2.25) |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brambilla, 200950  (continued) |  |  |  | G2: reduction in weight correlated positively with EDI-2 ineffectiveness (p=0.02, T=2.86)  G3: reduction in weight correlated negatively with SCL-90-R obsessivity-compulsivity (p=0.05, T=-2.5) and psychoticism (p=0.02, T=-3.2)  Article also states that "no correlations emerged between weight changes and PDQ-4-R data," although this contradicts the significant correlation found between G1 and PDQ-4-R negativism |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Claudino, 200751 | Weight, kg  Body Mass Index (BMI) | Weight, mean (SD)  G1: 96.6 (16.7)  G2: 98.4 (10.9)  p = 0.23  BMI, mean (SD)  G1: 37.4 (4.9)  G2: 37.4 (3.5)  p = 0.93 | Weight, mean (SD)  G1: 89.8 (13.4)  G2: 97.5 (10.5)  Group X time rate of change, p < 0.001  BMI, mean (SD)  G1: 35.0 (3.5)  G2: 36.7 (4.7)  Group X time rate of change, p = 0.0002 | NA | NA | NA |
| Devlin, 200752  Devlin, 200553 | Weight (kg) | Pre-treatment weight (kg) mean (SD)  Overall: 115 (21.8)  G1: 116.9 (20.8)  G2: 116.5 (22.2)  G3: 113.8 (22.9)  G4: 113.5 (22.2) | Post-treatment weight (kg) mean (SD)  Overall: 113 (23.6)  G1: 112.8 (22.7)  G2: 114.6 (23.0)  G3: 111.9 (27.1)  G4: 111.1 (21.9)  Group X time, p=NS  6 months weight (kg) mean (SD)  Overall: 111 (23.2)  G1: NR  G2: NR  G3: NR  G4: NR  12 months weight (kg) mean (SD)  Overall: 111 (23.2)  G1: NR  G2: NR  G3: NR  G4: NR | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Devlin, 200752  Devlin, 200553  (continued) |  |  | 18 months weight (kg) mean (SD)  Overall: 113 (23.2)  G1: NR  G2: NR  G3: NR  G4: NR  24 months weight (kg) mean (SD)  Overall: 115 (23.6)  G1: NR  G2: NR  G3: NR  G4: NR  Estimated change in weight over 24 months mean (SE): 0.484 (0.309)  G1: NR  G2: NR  G3: NR  G4: NR  Individual CBT (G1&G3 vs. G2&G4): F=0.01, p=0.911  Medication: (G1&G2 vs. G3&G4): F=0.01, p=0.914  Time: F=2.46, p=0.119  CBT-by-time: NS  Medication-by-time: NS |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Golay, 200554 | Body fat mass-bioelectrical impedence, %  Waist circumference, cm  Hip circumference, cm  Total energy expenditure [kcal/d] | Body fat mass-bioelectrical impedence  G1: 44.6 (0.9)  G2: 44.7 (1.0)  p = NR  Waist circumference, mean (SEM)  G1: 103.7 (1.8)  G2: 107.0 (1.6)  p = NR  Hip circumference, mean (SEM)  G1: 121.1 (9.2)  G2: 120.3 (9.5)  p = NR  Total energy expenditure, mean (SEM)  G1: 2275 (344.7)  G2: 2385 (356.0)  p = NR | Body fat mass-bioelectrical impedence, %  G1: 41.3 (1.0)  G2: 43.1 (1.0)  p = 0.023  Waist circumference, mean (SEM)  G1: 96.5 (1.8)  G2: 101.0 (1.5)  p = 0.005  Hip circumference, mean (SEM)  G1: 114.5 (8.2)  G2: 116.6 (9.3)  p < 0.001  Total energy expenditure, mean (SEM)  G1: 2158 (327.0)  G2: 2238 (334.0)  p = NS | Total cholesterol, mM  Low-density cholesterol (LDL), mM  High-density cholesterol (HDL), mM  Triglycerides, mM  Systolic Blood Pressure (SBP), mmHg  Diastolic BP (DBP), mmHg  Glucose, mg/dL  Insulin, pM  Leptin, micrograms/L | Total cholesterol, mean (SEM)  G1: 5.8 (0.9)  G2: 5.8 (0.9)  p = NR  LDL, mean (SEM)  G1: 3.5 (0.5)  G2: 3.6 (0.5)  p = NR  HDL, mean (SEM)  G1: 1.5 (0.2)  G2: 1.4 (0.2)  p = NR  Triglycerides, mean (SEM)  G1: 1.7 (0.2)  G2: 1.8 (0.3)  p = NR  SBP, mean (SEM)  G1: 123.2 (18.6)  G2: 122.1 (18.2)  p = NR  DBP, mean (SEM)  G1: 81.1 (12.3)  G2: 80.5 (12.0)  p = NR  Glucose, mean (SEM)  G1: 5.8 (0.9)  G2: 6.0 (0.9)  p = NR  Insulin, mean (SEM)  G1: 147.0 (22.3)  G2: 137.5 (20.5)  p = NR | Total cholesterol, mean (SEM)  G1: 5.3 (0.8)  G2: 5.7 (0.9)  p = 0.029  LDL, mean (SEM)  G1: 3.4 (0.5)  G2: 3.6 (0.5)  p = 0.090  HDL, mean (SEM)  G1: 1.4 (0.2)  G2: 1.4 (02)  p = NS  Triglycerides, mean (SEM)  G1: 1.2 (0.2)  G2: 1.5 (0.2)  p = 0.067  SBP, mean (SEM)  G1: 122.0 (18.2)  G2: 121.5 (18.0)  p = NS  DBP, mean (SEM)  G1: 78.0 (11.8)  G2: 81.7 (12.4)  p = 0.048  Glucose, mean (SEM)  G1: 5.5 (0.8)  G2: 5.9 (0.9)  p = 0.070  Insulin, mean (SEM)  G1: 114.5 (17.3)  G2: 144.4 (21.5)  p = 0.045 |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Golay, 200554  (continued) |  |  |  |  | Leptin, mean (SEM)  G1: 28.8 (4.4)  G2: 27.1 (4.0)  p = NR | Leptin, mean (SEM)  G1: 23.6 (3.6)  G2: 23.9 (3.6)  p = NS |
| Grilo, 200555 | BMI  Weight loss  Percentage weight loss  5% weight loss | BMI  G1: 36.2 (SD 4.7)  G2: 36.8 (SD 5.1)  p=0.67 | Post-treatment BMI  G1: NR  G2: NR  p=NR  3m BMI  G1: NR  G2: NR  p=NR  Post-treatment Weight loss (kg)  G1: 3.5 (SD 3.5)  G2: 1.6 (SD 2.4)  F=5.57  p=0.02  3m Weight loss (kg), mean  G1: 3.4 (SD 5.0)  G2: 1.3 (SD 3.1)  F=3.05  p=0.09  Post-treatment % weight loss  G1: 3.3 (SD 3.3)  G2: 1.6 (SD 2.4)  F=4.52  p=0.04  3m % weight loss  G1: 3.3 (SD 5.0)  G2: 1.3 (SD 3.0)  F=2.69  p=0.10 | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Grilo, 200555  (continued) |  |  | Post-treatment 5% weight loss, ITT analysis  G1: 36%  G2: 8%  chi-square=5.711  p=0.017  3m 5% weight loss, ITT analysis  G1: 32%  G2: 8%  chi-square=4.50  p=0.034  Post-treatment 5% weight loss, completers  G1: 47%  G2: 10%  chi-square=6.72  p=0.01  3m 5% weight loss, completers  G1: 42%  G2: 10%  chi-square=5.27  p=0.022 |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Grilo, 201356 | Body Mass Index (BMI) | BMI, mean  G1: 39.0 (SD 7.0)  G1: 37.2 (SD 5.3)  p=NR, NS | Post-treatment BMI  G1: 37.9 (SD 6.9)  G2: 36.0 (SD 5.0)  Groups did not differ significantly in improvements (p=NR, NS)  6m BMI  G1: 37.6 (SD 5.7)  G2: 36.7 (SD 5.3)  Groups did not differ significantly in improvements (p=NR, NS) | NA | NA | NA |
| Grilo, 200557  Grilo, 201258  Grilo, 201259  Grilo, 200660 | Body Mass Index (BMI)  Weight loss, lbs | BMI, mean (SD)  G1: 38.9 (9.5)  G2: 35.7 (7.2)  G3: 35.7 (8.3)  G4: 35.0 (6.2)  F:1.30  p=0.279 | BMI, mean (SD):  G1: 38.1 (9.6)  G2: 35.7 (7.5)  G3: 34.9 (7.9)  G4: 34.2 (5.8)  ANCOVA p=ns  G2 v G1: p=na  G4 v G3: p=na  G4 v G2: p=na  G4 v G1: p=na  G3 v G2: p=na  G3 v G1: p=na  6-month followup  G1: 36.1 (0.6)  G3: 36.9 (0.6)  G4: 35.9 (0.5)  12-month followup  G1: 36.2 (0.6)  G3: 35.8 (0.6)  G4: 34.8 (0.5) | NR | NR | NR |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Grilo, 200557  Grilo, 201258  Grilo, 201259  Grilo, 200660  (continued) |  |  | Mixed-model, p=NR, stated = significant  G4 v. G3: p=0.253  G4 v. G1: p=0.313  G3 v. G1: p=0.908  Weight loss, estimated marginal mean(SE)  Post-treatment  G1: -4.8 (3.0)  G3 -5.6 (2.9)  G4 -5.0 (2.8)  6-month followup  G1: -2.3 (3.6)  G3: -2.8 (3.1)  G4: -2.8 (3.1)  12-month followup  G1: -1.5 (3.5)  G3: -4.1 (3.6)  G4: -9.8 (3.2)  Mixed-model, p=NR, stated = significant  G4 v. G3: p=0.350  G4 v. G1: p=0.405  G3 v. G1: p=0.929 |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Laederach-Hofmann, 199961 | Weight, kg  Body mass index (BMI) | Weight, mean (SD)  G1: 96.0 (14.2)  G2: 114.8 (29.5)  p<0.05  BMI, mean (SD)  G1: 36.1 (6.3)  G2: 43.2 (9.4  p<0.02 | Weight, mean (SD)  8 wks  G1: 93. 8(14.4)  G2: 113.0 (29.4)  % change (data in figure), p < 0.05  32 wks  G1: 90.8 (13.5)  G2: 117.0 (29.2)  % change (data in figure), p=0.0003  BMI, mean (SD)  NR | Waist to hip ratio  Blood pressure, systolic (mmHg)  Blood pressure, diastolic (mmHg)  Serum glucose (mmol/l)  Total serum cholesterol (mmol/l) | Waist to hip ratio, mean (SD)  G1: 0.96 (0.007)  G2: 1.01 (0.07)  p=NS  Blood pressure, systolic (mmHg):  G1: 132.2 (18.0)  G2: 131.4 (13.5)  p=NS  Blood pressure, diastolic (mmHg)  G1: 87.0 (9.4)  G2: 87.5 (9.1)  p=NS  Serum glucose (mmol/l)  G1: 5.6 (1.2)  G2: 5.7 (1.3)  p=NS  Total serum cholesterol (mmol/l)  G1: 5.3 (1.1)  G2: 5.5 (0.9)  p=NS | "Systolic and diastolic blood pressure, serum cholesterol, and gluclose concentration as well as the other hematochemical parameters and wait-to-hip ratio remained stable during the 8-week study in both groups." |
| Lanzarone, 201462 | Percentage weight loss |  |  |  |  |  |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Molinari, 200563 |  | n/a | 3m achieved weight loss of at least 5% of initial weight  G1: 100%  G2: 100%  G3: 100%  6m % weight loss  G1: 5.25 (SD 1.30)  G2: 6.62 (SD 2.74)  G3: 7.32 (SD 0.88)  p=NR, NS  12m % weight loss  G1: 7.53 (SD 3.57)  G2: 0.19 (SD 2.74)  G3: 6.78 (SD 3.94)  p=0.001 | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Ricca, 200164 | 5% weight loss | BMI Overall: 32.3 (SD 5.8)  G1: 32.0 (SD 6.0)  G2: 31.7 (SD 5.6)  G3: 32.5 (SD 6.1)  G4: 32.1 (SD 3.8)  G5: 32.7 (SD 4.1) | 24 weeks (end of treatment) (presented in bar graph only so means not discernable)  G1: NR, p<0.01 vs. baseline  G2: NR, p<0.01 vs. baseline  G3: NR, p<0.01 vs. baseline  G4: NR  G5: NR  1 year after end of treatment (presented in bar graph only so means not discernable)  G1: NR, p<0.01 vs. baseline  G2: NR, p<0.01 vs. baseline  G3: NR, p<0.01 vs. baseline  G4: NR  G5: NR  G1, G2, and G3 showed increased BMI compared with 24wk but significantly lower than baseline; G4 and G5 showed no significant difference in 1y vs. baseline | NA | NA | NA |

Evidence Table 44. Binge eating disorder behavioral and drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition Of Weight Related Measure(S) | Weight Related Baseline | Weight Related Outcomes | Definition Of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Ricca, 200965 | Body mass index (BMI) | BMI  G1: 39.21 (SD 7.82)  G2: 38.43 (SD 5.70) | 24wk BMI  G1: 38.41 (SD 7.67)  G2: 36.77 (SD 5.84)  G2 had greater reduction, p<0.01  18m BMI  G1: 38.99 (SD 7.02)  G2: 36.49 (SD 5.96)  p=NR | NA | NA | NA |